Published in Lancet on July 21, 2007
Effectiveness of the Diaphragm for HIV Prevention | NCT00121459
Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42
Targeting early infection to prevent HIV-1 mucosal transmission. Nature (2010) 5.05
Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS (2010) 4.20
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS (2010) 4.05
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One (2008) 3.32
Setting the stage: host invasion by HIV. Nat Rev Immunol (2008) 3.25
Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS (2010) 2.70
Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol (2009) 2.57
A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS (2008) 2.43
The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol (2009) 2.39
The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS One (2008) 2.23
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest (2008) 2.12
Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One (2008) 2.09
Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev (2009) 1.95
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med (2011) 1.89
Using regression models to analyze randomized trials: asymptotically valid hypothesis tests despite incorrectly specified models. Biometrics (2009) 1.77
Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol (2008) 1.71
Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med (2015) 1.61
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
HIV prevention cost-effectiveness: a systematic review. BMC Public Health (2009) 1.58
Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One (2010) 1.55
Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr (2009) 1.49
Preventing HIV infection in women: a global health imperative. Clin Infect Dis (2010) 1.47
Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial. Clin Vaccine Immunol (2011) 1.47
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS Biol (2016) 1.43
Targeting the hotspots: investigating spatial and demographic variations in HIV infection in small communities in South Africa. J Int AIDS Soc (2010) 1.42
Vaginal practices, microbicides and HIV: what do we need to know? Sex Transm Infect (2007) 1.39
As the world grows: contraception in the 21st century. J Clin Invest (2008) 1.37
Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology (2009) 1.37
Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: a comparison of the two control arms of HPTN 035. J Acquir Immune Defic Syndr (2013) 1.33
Willingness to be circumcised for preventing HIV among Chinese men who have sex with men. AIDS Patient Care STDS (2009) 1.28
Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis (2009) 1.24
Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages. Am J Public Health (2012) 1.23
HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS (2009) 1.18
Good performance of rapid prostate-specific antigen test for detection of semen exposure in women: implications for qualitative research. Sex Transm Dis (2009) 1.16
Experiences in conducting multiple community-based HIV prevention trials among women in KwaZulu-Natal, South Africa. AIDS Res Ther (2010) 1.14
Twenty-five years of HIV: lessons for low prevalence scenarios. J Acquir Immune Defic Syndr (2009) 1.13
Screening for genital and anorectal sexually transmitted infections in HIV prevention trials in Africa. Sex Transm Infect (2008) 1.12
HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis (2010) 1.11
The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav (2011) 1.10
HIV incidence among non-pregnant women living in selected rural, semi-rural and urban areas in KwaZulu-Natal, South Africa. AIDS Behav (2012) 1.10
Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav (2009) 1.08
Vaginal practices and associations with barrier methods and gel use among Sub-Saharan African women enrolled in an HIV prevention trial. AIDS Behav (2010) 1.08
Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr (2013) 1.07
The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: a cohort study. BMJ Open (2012) 1.07
The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One (2008) 1.06
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health (2013) 1.05
Geoadditive models to assess spatial variation of HIV infections among women in local communities of Durban, South Africa. Int J Health Geogr (2011) 1.05
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials (2011) 1.04
Analyzing Direct Effects in Randomized Trials with Secondary Interventions: An Application to HIV Prevention Trials. J R Stat Soc Ser A Stat Soc (2009) 1.03
Randomised trials of HIV prevention. Lancet (2007) 1.02
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Estimating the effect of intimate partner violence on women's use of contraception: a systematic review and meta-analysis. PLoS One (2015) 0.99
Are hormonal contraceptive users more likely to misreport unprotected sex? Evidence from a biomarker validation study in Zimbabwe. AIDS Behav (2014) 0.99
Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction. J Int AIDS Soc (2014) 0.99
A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power. HIV Clin Trials (2010) 0.98
Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens. Curr Womens Health Rev (2008) 0.98
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J (2016) 0.94
A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. AIDS Behav (2011) 0.93
How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS One (2013) 0.92
Integrating HIV care and HIV prevention: legal, policy and programmatic recommendations. AIDS (2008) 0.92
Preconception care: delivery strategies and packages for care. Reprod Health (2014) 0.92
Geographical clustering of high risk sexual behaviors in "hot-spots" for HIV and sexually transmitted infections in Kwazulu-Natal, South Africa. AIDS Behav (2014) 0.92
An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc (2010) 0.92
Microbicides for HIV prevention. Indian J Med Res (2011) 0.90
Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90
Population-level impact of hormonal contraception on incidence of HIV infection and pregnancy in women in Durban, South Africa. Bull World Health Organ (2012) 0.90
High prevalence of obesity among women who enrolled in HIV prevention trials in KwaZulu-Natal, South Africa: healthy diet and life style messages should be integrated into HIV prevention programs. BMC Public Health (2013) 0.89
Chemokine expression patterns in the systemic and genital tract compartments are associated with HIV-1 infection in women from Benin. J Clin Immunol (2009) 0.89
Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa? Vaccine (2013) 0.88
Contraceptive methods and risk of HIV acquisition or female-to-male transmission. Curr HIV/AIDS Rep (2014) 0.88
Microbicides 2008 conference: from discovery to advocacy. AIDS Res Ther (2008) 0.88
Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol (2009) 0.88
Preconception care: preventing and treating infections. Reprod Health (2014) 0.87
HIV incidence and prevalence among cohorts of women with higher risk behaviour in Bloemfontein and Rustenburg, South Africa: a prospective study. BMJ Open (2012) 0.86
Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract. PLoS Pathog (2014) 0.86
Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis (2011) 0.86
Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. PLoS One (2012) 0.86
Contraception and HIV infection in women. Hum Reprod Update (2008) 0.85
Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings). Curr Opin HIV AIDS (2009) 0.85
Incidence of HIV in Windhoek, Namibia: demographic and socio-economic associations. PLoS One (2011) 0.84
HIV treatment proceeds as prevention research confounds. PLoS Med (2007) 0.84
Living with uncertainty: acting in the best interests of women. AIDS Res Treat (2012) 0.84
A Stochastic Model for Assessing Chlamydia trachomatis Transmission Risk Using Longitudinal Observational Data. J R Stat Soc Ser A Stat Soc (2011) 0.82
Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations. Sex Transm Dis (2012) 0.82
Clinical Trial Design for HIV Prevention Research: Determining Standards of Prevention. Bioethics (2014) 0.82
Predictors of retention among men attending STI clinics in HIV prevention programs and research: a case control study in Pune, India. PLoS One (2011) 0.81
Interim data monitoring to enroll higher-risk participants in HIV prevention trials. BMC Med Res Methodol (2009) 0.81
Preclinical, clinical, and over-the-counter postmarketing experience with a new vaginal cup: menstrual collection. J Womens Health (Larchmt) (2011) 0.81
High level of soluble HLA-G in the female genital tract of Beninese commercial sex workers is associated with HIV-1 infection. PLoS One (2011) 0.81
Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe. J Int AIDS Soc (2010) 0.81
High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa. AIDS Res Ther (2014) 0.80
Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. PLoS One (2014) 0.80
Challenges in the design of HIV prevention trials in the United States. J Acquir Immune Defic Syndr (2010) 0.80
Effect of treatment assignment on intravaginal cleansing in a randomized study of the diaphragm with candidate microbicide. J Womens Health (Larchmt) (2011) 0.80
Providing for women's pleasure in the next generation of condoms. J Sex Med (2013) 0.80
The Potential of Pre-Exposure Prophylaxis for Women in Violent Relationships. AIDS Patient Care STDS (2016) 0.80
Socio-demographic and behavioural characteristics associated with HSV-2 sero-prevalence in high risk women in KwaZulu-Natal. BMC Res Notes (2015) 0.79
Adherence to diaphragm use for infection prevention: a prospective study of female sex workers in Kenya. Infect Dis Obstet Gynecol (2010) 0.79
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (2007) 38.98
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
A multiple testing procedure for clinical trials. Biometrics (1979) 26.80
Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science (1998) 25.53
Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet (1995) 21.03
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Prevention of HIV infection in developing countries. Lancet (1996) 2.85
Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology (1995) 2.55
Microbicide acceptability research: current approaches and future directions. Soc Sci Med (2005) 2.54
Sexual behavior and STI/HIV status among adolescents in rural Malawi: an evaluation of the effect of interview mode on reporting. Stud Fam Plann (2008) 2.52
Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod (2005) 2.48
Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol (1998) 2.38
Transforming aids prevention to meet women's needs: a focus on developing countries. Soc Sci Med (1995) 2.37
Prostate-specific antigen to ascertain reliability of self-reported coital exposure to semen. Sex Transm Dis (2006) 2.31
Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis (1998) 2.27
Scientists rethink approach to HIV gels. Nature (2007) 2.14
In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5. J Virol (1998) 2.09
Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS (2000) 1.82
African women and AIDS: negotiating behavioral change. Soc Sci Med (1992) 1.79
Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS (2001) 1.75
Female control of sexuality: illusion or reality? Use of vaginal products in south west Uganda. Soc Sci Med (2001) 1.58
Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis (2001) 1.43
Audio computer-assisted self-interviewing in reproductive health research: reliability assessment among women in Harare, Zimbabwe. Contraception (2006) 1.37
Predictors of diaphragm use as a potential sexually transmitted disease/HIV prevention method in Zimbabwe. Sex Transm Dis (2005) 1.34
Barriers to preventing human immunodeficiency virus in women: experiences from KwaZulu-Natal, South Africa. J Am Med Womens Assoc (2001) 1.29
Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS (1998) 1.28
Assessing the acceptability, service delivery requirements, and use-effectiveness of the diaphragm in Colombia, Philippines, and Turkey. Contraception (2001) 1.10
Barrier method preferences and perceptions among Zimbabwean women and their partners. AIDS Behav (2005) 1.10
Acceptability and feasibility of continuous diaphragm use among sex workers in Madagascar. Sex Transm Infect (2005) 1.07
The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol (2002) 1.05
Use of male condoms during and after randomized, controlled trial participation in Cameroon. Sex Transm Dis (2005) 1.05
Measurement of anti-HIV activity of marketed vaginal products and excipients using a PBMC-based in vitro assay. Sex Transm Dis (2004) 1.00
Preventing sexual transmission of HIV: anti-HIV bioregulatory and homeostatic components of commercial sexual lubricants. J Biol Regul Homeost Agents (2005) 1.00
The importance of discreet use of the diaphragm to Zimbabwean women and their partners. AIDS Behav (2006) 1.00
Introducing diaphragms into the mix: what happens to male condom use patterns? AIDS Behav (2005) 0.97
The diaphragm with and without spermicide. A randomized, comparative efficacy trial. J Reprod Med (1995) 0.93
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med (2006) 5.73
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Should people at low risk of cardiovascular disease take a statin? BMJ (2013) 5.24
Hormonal contraception and the risk of HIV acquisition. AIDS (2007) 5.05
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis (2003) 4.49
To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology (2010) 4.34
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis (2008) 3.98
Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One (2008) 3.94
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Effects of body composition and leisure-time physical activity on transitions in physical functioning in the elderly. Am J Epidemiol (2005) 3.40
Early age of first sex: a risk factor for HIV infection among women in Zimbabwe. AIDS (2004) 3.30
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28
Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol (2005) 3.19
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
High HIV prevalence among men who have sex with men in Soweto, South Africa: results from the Soweto Men's Study. AIDS Behav (2009) 3.06
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Regression of low-grade squamous intra-epithelial lesions in young women. Lancet (2004) 2.98
Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol (2006) 2.94
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
HIV-1-discordant couples in sub-Saharan Africa: explanations and implications for high rates of discordancy. Curr HIV Res (2007) 2.78
Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med (2011) 2.76
Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol (2009) 2.57
Microbicide acceptability research: current approaches and future directions. Soc Sci Med (2005) 2.54
Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS (2007) 2.35
Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis (2004) 2.29
Leisure-time physical activity and all-cause mortality in an elderly cohort. Epidemiology (2009) 2.29
Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS (2007) 2.23
Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS (2010) 2.23
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
An application of model-fitting procedures for marginal structural models. Am J Epidemiol (2005) 2.14
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS (2010) 2.13
A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol (2003) 2.11
Alcohol and sexual risk behavior among men who have sex with men in South african township communities. AIDS Behav (2008) 2.06
Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians. Am J Hypertens (2007) 2.06
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav (2013) 2.03
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol (2010) 1.94
Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med (2011) 1.89
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis (2002) 1.88
A method to increase the power of multiple testing procedures through sample splitting. Stat Appl Genet Mol Biol (2006) 1.81
Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr (2008) 1.80
Identification of regulatory elements using a feature selection method. Bioinformatics (2002) 1.80
Sexual bridging socially and over time: a simulation model exploring the relative effects of mixing and concurrency on viral sexually transmitted infection transmission. Sex Transm Dis (2006) 1.78
Clinic Design and Continuity in Internal Medicine Resident Clinics: Findings of the Educational Innovations Project Ambulatory Collaborative. J Grad Med Educ (2015) 1.76
Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis (2009) 1.73
The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One (2009) 1.72
Children's perspectives on their relationships with their nonresident fathers: influences, outcomes and implications. J Child Psychol Psychiatry (2004) 1.68
Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS (2010) 1.68
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Assessing the reporting of adherence and sexual activity in a simulated microbicide trial in South Africa: an interview mode experiment using a placebo gel. AIDS Behav (2011) 1.68
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res (2009) 1.66
Site-specific interventions to improve prevention of mother-to-child transmission of human immunodeficiency virus programs in less developed settings. Am J Obstet Gynecol (2007) 1.66
Sexual behavior and reproductive health among HIV-infected patients in urban and rural South Africa. J Acquir Immune Defic Syndr (2008) 1.66
How reliable are tests for trachoma?--a latent class approach. Invest Ophthalmol Vis Sci (2011) 1.65
Acceptability of Carraguard vaginal gel use among Thai couples. AIDS (2006) 1.65
The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS (2012) 1.64
Better than nothing or savvy risk-reduction practice? The importance of withdrawal. Contraception (2009) 1.62
Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav (2010) 1.60
Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol (2008) 1.60
A randomized, controlled trial of in-home drinking water intervention to reduce gastrointestinal illness. Am J Epidemiol (2005) 1.59
Cravings as a mediator and moderator of drinking outcomes in the COMBINE study. Addiction (2013) 1.59
Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS (2012) 1.55
Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One (2010) 1.55
Quasi-experimental designs in practice-based research settings: design and implementation considerations. J Am Board Fam Med (2011) 1.51
Men and antiretroviral therapy in Africa: our blind spot. Trop Med Int Health (2011) 1.50
International survey on variations in practice of the management of the third stage of labour. Bull World Health Organ (2003) 1.50
Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol (2004) 1.50
Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses (2012) 1.50
Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol (2009) 1.49
5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene. Int J Biochem Cell Biol (2010) 1.48
Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates. Am J Epidemiol (2002) 1.48
Maternal smoking, alcohol drinking, and febrile convulsion. Seizure (2007) 1.48
Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol (2006) 1.48
Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa. AIDS (2010) 1.47
Incidence of acute urinary tract infection in young women and use of male condoms with and without nonoxynol-9 spermicides. Epidemiology (2002) 1.47